Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors
Conditions
Interventions
TAC01-CLDN18.2
Locations
9
United States
University of Southern California
Los Angeles, California, United States
University of California San Diego
San Diego, California, United States
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Cincinnati Cancer Center
Cincinnati, Ohio, United States
Start Date
August 23, 2023
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
February 14, 2025
NCT06307795
NCT06716138
NCT04585750
NCT05004116
NCT07213830
NCT05753722
Lead Sponsor
Triumvira Immunologics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions